Veterinary World (Oct 2021)
The therapeutic potential of the novel angiotensin-converting enzyme 2 in the treatment of coronavirus disease-19
- Ademola Adetokunbo Oyagbemi,
- Temitayo Olabisi Ajibade,
- Yapo Guillaume Aboua,
- Idayat Titilayo Gbadamosi,
- Aduragbenro Deborah A. Adedapo,
- Abimbola Obemisola Aro,
- Olumuyiwa Abiola Adejumobi,
- Emma Thamahane-Katengua,
- Temidayo Olutayo Omobowale,
- Olufunke Olubunmi Falayi,
- Taiwo Olaide Oyagbemi,
- Blessing Seun Ogunpolu,
- Fasilat Oluwakemi Hassan,
- Iyanuoluwa Omolola Ogunmiluyi,
- Olufunke Eunice Ola-Davies,
- Adebowale Benard Saba,
- Adeolu Alex Adedapo,
- Sanah Malomile Nkadimeng,
- Lyndy Joy McGaw,
- Prudence Ngalula Kayoka-Kabongo,
- Momoh Audu Yakubu,
- Oluwafemi Omoniyi Oguntibeju
Affiliations
- Ademola Adetokunbo Oyagbemi
- ORCiD
- Department of Veterinary Physiology and Biochemistry, Faculty of Veterinary Medicine, University of Ibadan, Nigeria.
- Temitayo Olabisi Ajibade
- ORCiD
- Department of Veterinary Physiology and Biochemistry, Faculty of Veterinary Medicine, University of Ibadan, Nigeria.
- Yapo Guillaume Aboua
- ORCiD
- Department of Health Sciences, Faculty of Health and Applied Sciences, Namibia University of Science and Technology, Private Bag 13388, Namibia.
- Idayat Titilayo Gbadamosi
- ORCiD
- Department of Botany, Faculty of Science, University of Ibadan, Nigeria.
- Aduragbenro Deborah A. Adedapo
- ORCiD
- Department of Pharmacology and Therapeutics, University of Ibadan, Nigeria.
- Abimbola Obemisola Aro
- ORCiD
- Department of Agriculture and Animal Health, College of Agriculture and Environmental Sciences, University of South Africa, Florida, South Africa.
- Olumuyiwa Abiola Adejumobi
- ORCiD
- Department of Veterinary Medicine, Faculty of Veterinary Medicine, University of Ibadan, Nigeria.
- Emma Thamahane-Katengua
- ORCiD
- Department of Health Information Management, Botho University, Faculty of Health and Education, Botswana.
- Temidayo Olutayo Omobowale
- ORCiD
- Department of Veterinary, Faculty of Veterinary Medicine, University of Ibadan, Nigeria.
- Olufunke Olubunmi Falayi
- ORCiD
- Department of Veterinary Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Ibadan, Nigeria.
- Taiwo Olaide Oyagbemi
- ORCiD
- Department of Veterinary Parasitology and Entomology, Faculty of Veterinary Medicine, University of Ibadan, Nigeria.
- Blessing Seun Ogunpolu
- ORCiD
- Department of Veterinary, Faculty of Veterinary Medicine, University of Ibadan, Nigeria.
- Fasilat Oluwakemi Hassan
- ORCiD
- Department of Veterinary Physiology and Biochemistry, Faculty of Veterinary Medicine, University of Ibadan, Nigeria.
- Iyanuoluwa Omolola Ogunmiluyi
- ORCiD
- Department of Veterinary Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Ibadan, Nigeria.
- Olufunke Eunice Ola-Davies
- ORCiD
- Department of Veterinary Physiology and Biochemistry, Faculty of Veterinary Medicine, University of Ibadan, Nigeria.
- Adebowale Benard Saba
- ORCiD
- Department of Veterinary Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Ibadan, Nigeria.
- Adeolu Alex Adedapo
- ORCiD
- Department of Veterinary Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Ibadan, Nigeria.
- Sanah Malomile Nkadimeng
- ORCiD
- Department of Paraclinical Science, Phytomedicine Programme, University of Pretoria, Faculty of Veterinary Science, Old Soutpan Road, Onderstepoort, 0110, South Africa.
- Lyndy Joy McGaw
- ORCiD
- Department of Paraclinical Science, Phytomedicine Programme, University of Pretoria, Faculty of Veterinary Science, Old Soutpan Road, Onderstepoort, 0110, South Africa.
- Prudence Ngalula Kayoka-Kabongo
- ORCiD
- Department of Agriculture and Animal Health, College of Agriculture and Environmental Sciences, University of South Africa, Florida, South Africa.
- Momoh Audu Yakubu
- ORCiD
- Department of Department of Environmental and Interdisciplinary Sciences, College of Science, Engineering and Technology, Vascular Biology Unit, Center for Cardiovascular Diseases, Texas Southern University, Houston, TX, USA.
- Oluwafemi Omoniyi Oguntibeju
- ORCiD
- Department of Biomedical Sciences, Phytomedicine and Phytochemistry Group, Oxidative Stress Research Centre, Faculty of Health and Wellness Sciences, Cape Peninsula University of Technology, Bellville 7535, South Africa.
- DOI
- https://doi.org/10.14202/vetworld.2021.2705-2713
- Journal volume & issue
-
Vol. 14,
no. 10
pp. 2705 – 2713
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent of coronavirus disease 2019 (COVID-19). This virus has become a global pandemic with unprecedented mortality and morbidity along with attendant financial and economic crises. Furthermore, COVID-19 can easily be transmitted regardless of religion, race, sex, or status. Globally, high hospitalization rates of COVID-19 patients have been reported, and billions of dollars have been spent to contain the pandemic. Angiotensin-converting enzyme (ACE) 2 is a receptor of SARS-CoV-2, which has a significant role in the entry of the virus into the host cell. ACE2 is highly expressed in the type II alveolar cells of the lungs, upper esophagus, stratified epithelial cells, and other tissues in the body. The diminished expressions of ACE2 have been associated with hypertension, arteriosclerosis, heart failure, chronic kidney disease, and immune system dysregulation. Overall, the potential drug candidates that could serve as ACE2 activators or enhance the expression of ACE2 in a disease state, such as COVID-19, hold considerable promise in mitigating the COVID-19 pandemic. This study reviews the therapeutic potential and pharmacological benefits of the novel ACE2 in the management of COVID-19 using search engines, such as Google, Scopus, PubMed, and PubMed Central.
Keywords
